At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 43 enrolled
Drug / intervention
HLD200 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Clinical Endpoint Evaluation Study Examining the Safety and Efficacy of HLD200 in Pediatric Subjects With Attention-Deficit Hyperactivity Disorder.
Ironshore Pharmaceuticals and Development, Inc·interventional·Posted Oct 2, 2014·Updated Jun 30, 2021
In Brief
A Phase 3 clinical trial evaluating HLD200 and Placebo for Attention Deficit Hyperactivity Disorder. Completed, enrolled 43 participants across 4 sites.
Detailed Summary
This study will examine the efficacy and safety of HLD200 in patients age 6-12 years with ADHD using a classroom study design.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMay 2014
Primary CompletionOct 2014
First PostedOct 2014
TodayJul 2026
First PostedOct 2, 2014
Enrollment StartMay 1, 2014
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 11.8 years ago
Interventions
HLD200drug
Placebodrug